Condition: Non Small Cell Lung Cancer · Stage III Lung Cancer · Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
This study investigates whether postoperative radiotherapy (PORT) improves outcomes for patients with stage III non-small cell lung cancer (NSCLC) who have residual disease after neoadjuvant chemo-immunotherapy and surgery. The primary objective is to compare event-free survival (EFS) between patients receiving PORT targeting involved lymph node regions and those without PORT. Secondary and tertiary endpoints include overall survival, locoregional and distant control, toxicity, and quality of life. The phase II randomized trial will enroll 118 patients, stratifying by adjuvant immunotherapy use, with follow-up extending up to 5 years. Statistical analysis aims to detect a 15% improvement in 2-year EFS, with a total study duration of 7 years.
This description comes directly from the study's public registry record.
Houda Bahig, MD PhD · 514-890-8254 · houda.bahig.med@ssss.gouv.qc.ca
Mom Phat · 514-890-8254 · mom.phat.chum@ssss.gouv.qc.ca
Always discuss trial participation with your own doctor first.
| Centre Hospitalier de l'Université de Montréal | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06878274